Early-stage trial of Amgen's cholesterol drug yields positive results

03/25/2012 | Reuters

A Phase I trial showed that monthly injection of Amgen's investigational drug AMG 145 reduces bad cholesterol by as much as an additional 66% in patients already taking low to moderate doses of statins. AMG145 works by inhibiting the PCSK9 protein. A similar drug, REGN 727, is being developed by Regeneron Pharmaceuticals.

View Full Article in:


Published in Brief: